Five Prime Therapeutics Inc. (FPRX)

10.64
NASDAQ : Health Technology
Prev Close 10.64
Day Low/High 0.00 / 0.00
52 Wk Low/High 7.84 / 22.84
Avg Volume 375.00K
Exchange NASDAQ
Shares Outstanding 35.47M
Market Cap 356.08M
EPS -5.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Five Prime Therapeutics Announces Two Poster Presentations At The 2019 Gastrointestinal Cancers Symposium

Five Prime Therapeutics Announces Two Poster Presentations At The 2019 Gastrointestinal Cancers Symposium

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced two upcoming presentations at the 2019 Gastrointestinal Cancer...

Five Prime Therapeutics To Present At The 37th Annual J.P. Morgan Healthcare Conference

Five Prime Therapeutics To Present At The 37th Annual J.P. Morgan Healthcare Conference

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that Aron Knickerbocker, Chief Executive Officer, will present at the 37 th...

Five Prime Therapeutics Announces Changes To Its Board Of Directors

Five Prime Therapeutics Announces Changes To Its Board Of Directors

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced today changes to its Board of Directors.

Five Prime Therapeutics To Present At 30th Annual Piper Jaffray Healthcare Conference

Five Prime Therapeutics To Present At 30th Annual Piper Jaffray Healthcare Conference

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that Aron Knickerbocker, Chief Executive Officer, will present at the 30 th...

Five Prime Therapeutics Initiates Patient Dosing In A Phase 1 Clinical Trial Of FPT155, A First-in-Class CD80 Fusion Protein

Five Prime Therapeutics Initiates Patient Dosing In A Phase 1 Clinical Trial Of FPT155, A First-in-Class CD80 Fusion Protein

Five Prime Therapeutics, Inc. (Nasdaq: FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced it initiated patient dosing in a Phase 1 clinical trial of FPT155, a first-in-class CD80...

Five Prime Therapeutics Announces Third Quarter 2018 Financial Results

Five Prime Therapeutics Announces Third Quarter 2018 Financial Results

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today provided a corporate update and reported financial results for the fiscal...

Five Prime Therapeutics Announces David V. Smith Will Join As Chief Financial Officer

Five Prime Therapeutics Announces David V. Smith Will Join As Chief Financial Officer

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced that industry veteran David V.

Five Prime Therapeutics To Announce Third Quarter 2018 Financial Results And Host Conference Call On November 6

Five Prime Therapeutics To Announce Third Quarter 2018 Financial Results And Host Conference Call On November 6

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, will report its third quarter 2018 financial results on Tuesday, Nov.

Five Prime Therapeutics Initiates Patient Dosing In The Dose Exploration Cohort Of Its Phase 1 Trial Of Novel First-in-Class B7-H4 Antibody FPA150

Five Prime Therapeutics Initiates Patient Dosing In The Dose Exploration Cohort Of Its Phase 1 Trial Of Novel First-in-Class B7-H4 Antibody FPA150

Five Prime Therapeutics, Inc. (Nasdaq: FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that it initiated patient dosing in the dose exploration cohort of its ongoing Phase 1...

Five Prime Therapeutics And Zai Lab Dosed First Patient In Phase 3, Global Registrational Trial Of Bemarituzumab In Front-Line Advanced Gastric And Gastroesophageal Junction Cancers

Five Prime Therapeutics And Zai Lab Dosed First Patient In Phase 3, Global Registrational Trial Of Bemarituzumab In Front-Line Advanced Gastric And Gastroesophageal Junction Cancers

Five Prime Therapeutics, Inc. (Nasdaq: FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, and Zai Lab Limited (Nasdaq: ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced...

Five Prime Therapeutics To Present At Leerink Partners Roundtable Series: Rare Disease & Oncology

Five Prime Therapeutics To Present At Leerink Partners Roundtable Series: Rare Disease & Oncology

Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that Aron Knickerbocker, Chief Executive Officer, will present at the Leerink Partners...

Five Prime Therapeutics Is Now Oversold (FPRX)

Five Prime Therapeutics Is Now Oversold (FPRX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Five Prime Therapeutics Completes Phase 1 Safety Lead-In And Initiates Phase 3, Global Registrational Trial Of Bemarituzumab In Front-Line Advanced Gastric And Gastroesophageal Junction Cancers

Five Prime Therapeutics Completes Phase 1 Safety Lead-In And Initiates Phase 3, Global Registrational Trial Of Bemarituzumab In Front-Line Advanced Gastric And Gastroesophageal Junction Cancers

Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that the company completed the Phase 1 safety lead-in portion and has initiated the Phase 3...

Five Prime Therapeutics To Present At 2018 Wells Fargo Healthcare Conference

Five Prime Therapeutics To Present At 2018 Wells Fargo Healthcare Conference

Five Prime Therapeutics, Inc. (Nasdaq: FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that Aron Knickerbocker, Chief Executive Officer, will present at the 2018 Wells Fargo...

Five Prime Therapeutics Announces Second Quarter 2018 Financial Results

Five Prime Therapeutics Announces Second Quarter 2018 Financial Results

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today provided a corporate update and reported financial results for the fiscal...

Five Prime Therapeutics Becomes Oversold (FPRX)

Five Prime Therapeutics Becomes Oversold (FPRX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Five Prime Therapeutics To Announce Second Quarter 2018 Financial Results And Host Conference Call On August 8

Five Prime Therapeutics To Announce Second Quarter 2018 Financial Results And Host Conference Call On August 8

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, will report its second quarter 2018 financial results on Wednesday, August 8, 2018,...

Interesting FPRX Put And Call Options For August 17th

Interesting FPRX Put And Call Options For August 17th

Investors in Five Prime Therapeutics, Inc saw new options begin trading this week, for the August 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the FPRX options chain for the new August 17th contracts and identified one put and one call contract of particular interest.

Five Prime Therapeutics To Present At Goldman Sachs 39th Annual Global Healthcare Conference

Five Prime Therapeutics To Present At Goldman Sachs 39th Annual Global Healthcare Conference

Five Prime Therapeutics, Inc. (Nasdaq: FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that Aron Knickerbocker, Chief Executive Officer, will present at the Goldman Sachs 39th...

Five Prime Therapeutics Presents Bemarituzumab Trial-in-Progress Poster At The 2018 ASCO Annual Meeting

Five Prime Therapeutics Presents Bemarituzumab Trial-in-Progress Poster At The 2018 ASCO Annual Meeting

Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced that a poster titled "FIGHT: A Phase 3 Randomized, Double-Blind, Placebo...

Five Prime Therapeutics To Present At Jefferies 2018 Global Healthcare Conference

Five Prime Therapeutics, Inc. (Nasdaq: FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that Francis Sarena, Chief Strategy Officer, will present at the Jefferies 2018 Global...

Five Prime Therapeutics Appoints Bryan Irving, Ph.D., As Chief Scientific Officer

Five Prime Therapeutics Appoints Bryan Irving, Ph.D., As Chief Scientific Officer

Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced the appointment of Bryan Irving, Ph.

Five Prime Therapeutics Announces First Quarter 2018 Financial Results

Five Prime Therapeutics Announces First Quarter 2018 Financial Results

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today provided a corporate update and reported financial results for the fiscal...

Five Prime To Present At 2018 ASCO Annual Meeting

Five Prime To Present At 2018 ASCO Annual Meeting

Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced that it will present two posters during the 2018 American Society of...

Five Prime Therapeutics To Announce First Quarter 2018 Financial Results And Host Conference Call On May 8

Five Prime Therapeutics To Announce First Quarter 2018 Financial Results And Host Conference Call On May 8

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, will report its first quarter 2018 financial results on Tuesday, May 8, 2018,...

Five Prime Therapeutics Initiates Patient Dosing In Phase 1 Trial Of Novel First-in-Class B7-H4 Antibody FPA150

Five Prime Therapeutics Initiates Patient Dosing In Phase 1 Trial Of Novel First-in-Class B7-H4 Antibody FPA150

Five Prime Therapeutics, Inc. (Nasdaq: FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that it initiated patient dosing in its Phase 1...

TheStreet Quant Rating: D (Sell)